NCT01943526View on ClinicalTrials.gov

Ireland Natalizumab (TYSABRI) Observational Program

CompletedOBSERVATIONAL
Enrollment

191

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
BIOLOGICAL

natalizumab

Natalizumab will not be provided as a part of this study. Participants will receive natalizumab as prescribed by their treating physician.

Trial Locations (5)

Unknown

Research site, Cork

Research site, Dublin

Research site, Galway

Research site, Tralee

Research site, Sligo

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT01943526 - Ireland Natalizumab (TYSABRI) Observational Program | Biotech Hunter | Biotech Hunter